Delveinsight

DECEMBER 10, 2020

The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate. In a pooled analysis of 11,636 participants enrolled in two separate clinical trials in the U.K.

Gene Therapy 52

Gene Therapy Gene Vaccination Vaccine 52

The Pharma Data

DECEMBER 23, 2020

Joseph Kim , President and CEO of INOVIO, said, “We are very pleased to share peer-reviewed Phase 1 clinical data for INO-4800 published in The Lancet’s EClinicalMedicine , and are grateful for the support of all participants and investigator staff involved in the clinical trial.” mg and 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

APRIL 17, 2021

Biogen advances leading research to help inform future patient management including new information on the clinical profile of extended interval dosing with natalizumab. The research adds to the vast clinical knowledge Biogen continues to advance as part of its commitment to the care of people living with MS. CAMBRIDGE, Mass.,

Clinical Trials 52

Clinical Trials Clinical Trials Trials Radiology 52

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. To specifically target cancer cells, alpha-emitting radionuclides are often attached to molecules that have a high affinity for cancer cells, such as antibodies or peptides (ligands). Guarnaschelli in the webinar.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

NOVEMBER 18, 2021

Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic COVID-19, with no severe disease or deaths with AZD7442. Separate treatment trial showed 88% reduced risk of severe COVID-19 or death when treated within three days of symptom onset.

Trials 52

Trials Antibody In-Vitro Vaccination 52

The Pharma Data

MARCH 16, 2021

AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19. AZD7442 is currently being assessed in five late-stage prevention and treatment trials.

Antibody 52

Antibody Trials Radiology Development 52

XTalks

SEPTEMBER 14, 2020

By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

The Pharma Data

OCTOBER 12, 2021

Trial met primary endpoint. AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19. The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415). The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415).

Trials 52

Trials Development Antibody Radiology 52

pharmaphorum

OCTOBER 5, 2022

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir Biotechnology’s investigational prophylactic monoclonal antibody (mAb) for seasonal and pandemic influenza viruses.

Antibody 108

Antibody In-Vitro Radiology Development 108

XTalks

JUNE 12, 2023

These powerhouse organizations have not only distinguished themselves through their cutting-edge devices and technologies but also via their robust research and development (R&D) capabilities, unwavering commitment to quality and extensive global reach. The company reported an investment of $2.7

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

The Pharma Data

NOVEMBER 18, 2020

Eli Lilly and Company’s antibody therapeutic will be distributed as part of the federal government’s Operation Warp Speed. . 18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. TAMPA, Fla.,

Antibody 40

Antibody Medicine Radiology Protein 40

The Pharma Data

AUGUST 22, 2021

The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. The trial included 5,197 participants in a 2:1 randomisation AZD7442 to placebo. The trial was conducted in 87 sites in the US, UK, Spain, France and Belgium.

Trials 52

Trials Antibody Vaccination Vaccine 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials 52

Trials Antibody In-Vitro Medicine 52

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old).

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

The Pharma Data

OCTOBER 6, 2021

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Juncture Use Authorization (EUA) for AZD7442, its long- production antibody (LAAB) combination, for prophylaxis of proper COVID-19. The trial accrued 25 cases of discriminating COVID-19 at the primary analysis. AZD7442 was well- let.

Antibody 52

Antibody In-Vitro Trials Vaccination 52